insights_auto
Why is NBIX down 4.41%?
Dive Deeperchevron_right
NBIX:NASDAQ
Neurocrine Biosciences, Inc
$135.13
arrow_downward
-4.41%(-6.24) 1D
$135.13
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 13, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NBIX...
Open
$139.60
High
$139.92
Low
$134.89
Mkt. cap
13.74B
Avg. vol.
1.30M
Volume
1.57M
P/E ratio
19.81
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.82
Beta
0.40
Shares outstanding
101.65M
No. of employees
2K
Open
$139.60
High
$139.92
Low
$134.89
Mkt. cap
13.74B
Avg. vol.
1.30M
Volume
1.57M
P/E ratio
19.81
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.82
Beta
0.40
Shares outstanding
101.65M
No. of employees
2K
News stories
From web sources and news partners
GuruFocus
·
2 hours ago
Is Neurocrine Biosciences Inc (NBIX) a Bargain After 4.4% Drop? GF Value Says Undervalued
Insider Monkey
·
6 hours ago
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?
Zacks
·
8 hours ago
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?
Yahoo Finance Australia
·
9 hours ago
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2.5K
Founded1992
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteneurocrine.com